Elizabeth Katherine Anna Triumbari

Dr. Elizabeth Katherine Anna Triumbari

Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2022 in Seminars in Nuclear Medicine
Verified
Journal Article
Closed access
QNQuinn Kwan-Tai Ng
Quinn Kwan-Tai Ng
ETElizabeth Katherine Anna Triumbari
Elizabeth Katherine Anna Triumbari
NONegar Omidvari
Negar Omidvari
SCSimon R. Cherry
Simon R. Cherry
RBRamsey D. Badawi
Ramsey D. Badawi
LNLorenzo Nardo
Lorenzo Nardo

27 May 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
DMDavid Morland
David Morland
ETElizabeth Katherine Anna Triumbari
Elizabeth Katherine Anna Triumbari
LBLuca Boldrini
Luca Boldrini
RGRoberto Gatta
Roberto Gatta
DPDaniele Antonio PIzzuto
Daniele Antonio PIzzuto
Salvatore AnnunziataSalvatore Annunziata
Salvatore Annunziata
Radiomics is an upcoming field in nuclear oncology, both promising and technically challenging. To summarize the already undertaken work on supradiaphragmatic neoplasia and assess its quality, we performed a literature search in the PubMed database up to 18 February 2022. Inclusion criteria were: studies based on human data; at least one specified tumor type; supradiaphragmatic malignancy; performing radiomics on PET imaging. Exclusion criteria were: studies only based on phantom or animal data; technical articles without a clinically oriented question; fewer than 30 patients in the training cohort. A review database containing PMID, year of publication, cancer type, and quality criteria (number of patients, retrospective or prospective nature, independent validation cohort) was constructed. A total of 220 studies met the inclusion criteria. Among them, 119 (54.1%) studies included more than 100 patients, 21 studies (9.5%) were based on prospectively acquired data, and 91 (41.4%) used an independent validation set. Most studies focused on prognostic and treatment response objectives. Because the textural parameters and methods employed are very different from one article to another, it is complicated to aggregate and compare articles. New contributions and radiomics guidelines tend to help improving quality of the reported studies over the years.

3 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Filippo LococoFilippo Lococo
Filippo Lococo
MCMarco Chiappetta
Marco Chiappetta
ETElizabeth Katherine Anna Triumbari
Elizabeth Katherine Anna Triumbari
JEJessica Evangelista
Jessica Evangelista
MCMaria Teresa Congedo
Maria Teresa Congedo
SMStefano Margaritora
Stefano Margaritora
Background: The use of 18F FDG PET/CT scan in thymic epithelial tumours (TET) has been reported in the last two decades, but its application in different clinical settings has not been clearly defined. Methods: We performed a pictorial review of pertinent literature to describe different roles and applications of this imaging tool to manage TET patients. Finally, we summarized future prospects and potential innovative applications of PET in these neoplasms. Results: 18FFDG PET/CT scan may be of help to distinguish thymic hyperplasia from thymic epithelial tumours but evidences are almost weak. On the contrary, this imaging tool seems to be very performant to predict the grade of malignancy, to a lesser extent pathological response after induction therapy, Masaoka Koga stage of disease and long-term prognosis. Several other radiotracers have some application in TETs but results are limited and almost controversial. Finally, the future of PET/CT and theranostics in TETs is still to be defined but more detailed analysis of metabolic data (such as texture analysis applied on thymic neoplasms), along with promising preclinical and clinical results from new “stromal PET tracers”, leave us an increasingly optimistic outlook. Conclusions: PET plays different roles in the management of thymic epithelial tumours, and its applications may be of help for physicians in different clinical settings.

22 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ETElizabeth Katherine Anna Triumbari
Elizabeth Katherine Anna Triumbari
VRVittoria Rufini
Vittoria Rufini
CMClemens Mingels
Clemens Mingels
ARAxel Rominger
Axel Rominger
Abass AlaviAbass Alavi
Abass Alavi
LNLorenzo Nardo
Lorenzo Nardo
Gynecological malignancies currently affect about 3.5 million women all over the world. Imaging of uterine, cervical, vaginal, ovarian, and vulvar cancer still presents several unmet needs when using conventional modalities such as ultrasound, computed tomography (CT), magnetic resonance, and standard positron emission tomography (PET)/CT. Some of the current diagnostic limitations are represented by differential diagnosis between inflammatory and cancerous findings, detection of peritoneal carcinomatosis and metastases <1 cm, detection of cancer-associated vascular complications, effective assessment of post-therapy changes, as well as bone metabolism and osteoporosis assessment. As a result of recent advances in PET/CT instrumentation, new systems now offer a long-axial field-of-view (LAFOV) to image between 106 cm and 194 cm (i.e., total-body PET) of the patient’s body simultaneously and feature higher physical sensitivity and spatial resolution compared to standard PET/CT systems. LAFOV PET could overcome the forementioned limitations of conventional imaging and provide valuable global disease assessment, allowing for improved patient-tailored care. This article provides a comprehensive overview of these and other potential applications of LAFOV PET/CT imaging for patients with gynecological malignancies.

11 April 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ETElizabeth Katherine Anna Triumbari
Elizabeth Katherine Anna Triumbari
RGRoberto Gatta
Roberto Gatta
EMElena Maiolo
Elena Maiolo
MSMarco De Summa
Marco De Summa
LBLuca Boldrini
Luca Boldrini
Salvatore AnnunziataSalvatore Annunziata
Salvatore Annunziata
This study investigated the predictive role of baseline 18F-FDG PET/CT (bPET/CT) radiomics from two distinct target lesions in patients with classical Hodgkin’s lymphoma (cHL). cHL patients examined with bPET/CT and interim PET/CT between 2010 and 2019 were retrospectively included. Two bPET/CT target lesions were selected for radiomic feature extraction: Lesion_A, with the largest axial diameter, and Lesion_B, with the highest SUVmax. Deauville score at interim PET/CT (DS) and 24-month progression-free-survival (PFS) were recorded. Mann–Whitney test identified the most promising image features (p < 0.05) from both lesions with regards to DS and PFS; all possible radiomic bivariate models were then built through a logistic regression analysis and trained/tested with a cross-fold validation test. The best bivariate models were selected based on their mean area under curve (mAUC). A total of 227 cHL patients were included. The best models for DS prediction had 0.78 ± 0.05 maximum mAUC, with a predominant contribution of Lesion_A features to the combinations. The best models for 24-month PFS prediction reached 0.74 ± 0.12 mAUC and mainly depended on Lesion_B features. bFDG-PET/CT radiomic features from the largest and hottest lesions in patients with cHL may provide relevant information in terms of early response-to-treatment and prognosis, thus representing an earlier and stronger decision-making support for therapeutic strategies. External validations of the proposed model are planned.

18 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ETElizabeth Katherine Anna Triumbari
Elizabeth Katherine Anna Triumbari
DMDavid Morland
David Morland
Riccardo LaudicellaRiccardo Laudicella
Riccardo Laudicella
Matteo BaucknehtMatteo Bauckneht
Matteo Bauckneht
Domenico AlbanoDomenico Albano
Domenico Albano
Salvatore AnnunziataSalvatore Annunziata
Salvatore Annunziata
Objective: Immuno-positron emission tomography (iPET) combines the sensitivity of the PET imaging technique and the targeting specificity of radio-labelled monoclonal antibodies (mAb). Its first clinical applications in humans were described in the late 1990s, and several pathologies have benefitted from this molecular imaging modality since then. Our scope was to assess current clinical applications of immuno-PET in patients with lymphoma. Therefore, a systematic review of the published literature was performed. Methods: PubMed/Medline and Scopus databases were independently searched by two nuclear medicine physicians, to identify studies describing the clinical use of immuno-PET in patients with lymphoma. Methodological quality of the included articles was assessed by using the Quality Assessment of Diagnostic Accuracy Studies criteria. The studies were then analyzed concerning the molecular target of interest. Results: The initial search yielded 1407 articles. After elimination of duplicates, 1339 titles/abstracts were evaluated. Only two articles were found to comply with the inclusion criteria and two more were found during the cross-reference check. Among the four included articles, three described the use of 89Zr-labelled antibodies targeting CD20+ relapsed/refractory B-cell lymphomas and one concerned the use of 68Ga-labelled mAb targeting CXCR4 in patients with non-Hodgkin lymphomas. Conclusions: Very limited literature data are currently available on the clinical use of iPET in patients with lymphoma. This technique is encountering obstacles in its wider use, possibly because of the need of specific facilities, unfavorable dosimetry, and unclear correlation of immuno-tracer biodistribution with patients’ clinical and tumors’ molecular characteristics. However, iPET may represent a useful tool to non-invasively visualize the heterogenous individual immunological environment, thus potentially guiding treatment-planning in lymphoma patients, and hence deserves further exploitation.